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A B S T R A C T   
Adenosquamous carcinoma of the lung (ASC) is a rare subtype of non-small cell lung cancer, consisting of lung 
adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) components. ASC shows morphological 
characteristics of classic LUAD and LUSC but behaves more aggressively. Although ASC can serve as a model of 
lung cancer heterogeneity and transdifferentiation, its genomic background remains poorly understood. In this 
study, we sought to explore the genomic landscape of macrodissected LUAD and LUSC components of three ASC 
using whole exome sequencing (WES). Identified truncal mutations included the pan-cancer tumor-suppressor 
gene TP53 but also EGFR, BRAF, and MET, which are characteristic for LUAD but uncommon in LUSC. No truncal 
mutation of classical LUSC driver mutations were found. Both components showed unique driver mutations that 
did not overlap between the three ASC. Mutational signatures of truncal mutations differed from those of the 
branch mutations in their descendants LUAD and LUSC. Most common signatures were related to aging (1, 5) and 
smoking (4). Truncal chromosomal copy number aberrations shared by all three ASC included losses of 3p, 15q 
and 19p, and an amplified region in 5p. Furthermore, we detected loss of STK11 and SOX2 amplification in ASC, 
which has previously been shown to drive transdifferentiation from LUAD to LUSC in preclinical mouse models. 
Conclusively, this is the first study using WES to elucidate the clonal evolution of ASC. It provides strong evi-
dence that the LUAD and LUSC components of ASC share a common origin and that the LUAD component ap-
pears to transform to LUSC.   
1. Introduction 
Adenosquamous carcinoma (ASC) is a rare histological subtype of 
lung cancer accounting for 0.4 %–4 % of all lung cancers [1]. It consists 
of two morphologically distinct components including LUAD and LUSC 
[1]. From a clinical point of view, the biphasic ASC represents a chal-
lenge. It is more aggressive than its classical single components and has 
been shown to be associated with worse outcome [2]. There is no spe-
cific standard treatment for ASC, and current standard of care options 
rely on general non-small cell lung cancer (NSCLC) guidelines. Surgical 
resection is the only effective mean to treat patients with ASC, mostly in 
conjunction with platinum-based adjuvant chemotherapy [3]. Targeted 
treatments can be used as first-line therapy for advanced EGFR-mutant 
or ALK-rearranged ASC, but there are limited data on the efficacy of 
EGFR- or ALK-tyrosine kinase inhibitor (TKI) in ASC due to its rarity 
(reviewed in [4]). From a diagnostic perspective, it is challenging to 
grasp the biphasic nature of the tumor. Due to limited sampling by small 
biopsies, there is a high chance to miss one component so that the 
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subsequent treatment will be based on only one of the components. 
Previous studies focusing on oncogenic driver mutations revealed 
that ASC have similar mutation profiles and therapeutic targets as LUAD 
including EGFR mutations [5,6]. Yet, to the best of our knowledge, the 
genomic profiles of the LUAD and LUSC components within ASC and the 
inferred evolutionary trajectories have not been explored previously, 
beyond the use of single gene and gene panel testing [5,6]. Being defined 
by its distinct morphological heterogeneity, ASC represents an ideal 
model to study morphological transdifferentiation and clonal evolution 
in NSCLC. Common LUAD is considered to originate from stem cells at 
the bronchoalveolar junction, whereas LUSC derive from the more 
proximally located basal cell compartment of the bronchial epithelium 
[7]. Based on targeted sequencing, several mutations were detected in 
both components LUAD and LUSC of ASC suggesting the two entities 
share the same ancestor cell [5,6]. It has been hypothesized that they are 
likely to arise at the bronchoalveolar junction as LUAD and that the 
LUSC phenotype develops subsequently [5,6]. The molecular mecha-
nisms of this adenosquamous transdifferentiation (AST) remain 
unknown. 
This study aims at better understanding the genomic landscape and 
the evolutionary trajectories of ASC. To this end, we dissected the LUAD 
and LUSC components separately from three ASC patients for compre-
hensive genomic profiling of both components using whole exome 
sequencing (WES). 
2. Materials and methods 
2.1. Patient cohort & immunohistochemistry 
Three cases of ASC were retrieved from the pathology archive of the 
Institute of Pathology and Medical Genetics, University Hospital Basel, 
Switzerland. Representative formalin-fixed paraffin-embedded sections 
were cut (4 μm thick) and stained with hematoxylin and eosin. TTF-1, 
Napsin A, CK7 and p40 were used to distinguish LUAD and LUSC com-
ponents. TTF-1 (Ventana catalog number 790–7456), Napsin A (Ventana 
catalog number 760–4867), CK7 (Ventana catalog number 790-4462) 
and p40 (Ventana catalog number 790–4950) staining was performed 
on the Benchmark Ultra (Ventana, Roche) as described previously [8]. 
The sections were reviewed by a pulmonary pathologist (LB), who 
marked distinct morphological regions for macrodissection. FISH anal-
ysis was performed according to the manufactures protocol (ZytoLight® 
SPEC SOX2/CEN3 dual color probe, catalog number Z-2127− 200, 
Zytovision, Bremerhaven, Germany). This study has been carried out 
under the ethical approval EKNZ 31/12. 
2.2. Macrodissection and DNA extraction 
Up to ten consecutive 10 μm thick unstained tissue sections were cut 
on glass slides. The distinct morphological components and matched 
normal lung tissue were identified and marked by a pathologist (LB), 
scratched from the glass slide using a 25 g disposable syringe under a 
stereoscope as previously described [9]. Scratched cells were subjected 
to 200 μl of ATL buffer and 40 μl Proteinase K and incubated overnight at 
56 ◦C with 500 rpm using the reagents from DNeasy Blood and Tissue Kit 
(Qiagen, Germantown, MD, USA) according to the manufacturer’s in-
structions. DNA was quantified using the Qubit Fluorometer assay (Life 
Technologies, Carlsbad, CA, USA) as previously described [9]. 
2.3. Whole exome sequencing and variant annotation 
Extracted DNA from normal and macrodissected ASC components 
were subjected to WES. SureSelect Human All Exon V6 Kit (Agilent) was 
used for the whole exome capturing according to manufacturer’s 
guidelines. Sequencing was performed on Illumina NovaSeq 6000 using 
paired-end 100-bp reads and yielded a median depth of coverage of 48x 
to 120x in tumor components and 49x to 122x in the corresponding 
germlines (Supplementary Table 1). Sequencing was performed by 
CeGaT (Tübingen, Germany). 
Reads were aligned to the reference human genome GRCh37. So-
matic single nucleotide variants (SNVs) and small insertions and de-
letions (indels) were detected using MuTect (v.1.1.7) and Strelka 
(v.2.9.10), respectively [10,11]. To reduce false positive results from 
artifacts caused by formalin fixation, specific SNVs C:G > T:A with 
variant allelic fraction (VAF) less than 10 % were discarded. Otherwise, 
SNVs or indels with a VAF < 1% or that were covered by fewer than 3 
reads were discarded, if the SNVs were found in both components of one 
sample, a cut-off of two read was applied. We further excluded variants 
identified in at least two of a panel of 123 non-tumor samples, including 
the non-tumor samples included in the current study. Variant annotation 
was performed by SnpEff software v.4.1 [12]. 
The heatmap of non-synonymous mutations was generated using the 
R package maftools v.2.0.16 by selecting the genes in the Bailey et al. 
dataset that represents the significantly mutated genes in classic LUAD 
and LUSC obtained from TCGA [13]. 
2.4. Copy number aberration analysis and clonality analysis 
Allele-specific CNAs were identified using FACETS v.0.5.14 [14]. 
Deletions/losses were defined with the log-ratio < -0.3 and amplifica-
tions/gains > 0.3. Cancer cell fraction (CCF) of each mutation was 
identified using ABSOLUTE v.1.0.6 [15]. A mutation was classified as 
clonal if its probability of being clonal was > 50 % or if the lower bound 
of the 95 % confidence interval of its CCF was > 90 %. Mutations were 
considered as subclonal, if they did not meet the mentioned criteria [16, 
17]. A mutation that was found in both components of one biopsy was 
considered as ‘trunk’. Mutations that were detected in only one 
component of the tumor were granted as ‘branch’ or ‘private’. 
2.5. Phylogenetic analysis and mutational signatures 
A maximum parsimony tree was built for each case using binary 
presence/absence matrices based on the repertoire of non-synonymous 
and synonymous somatic mutations, gene amplifications and homozy-
gous deletions in the biopsies of the tumors, as described by Murugaesu 
et al. [18,19]. 
Decomposition of mutational signatures was conducted using the R 
package deconstructSigs by selecting mutational signatures based on the 
set of 30 mutational signatures (‘signature.cosmic’) that were observed 
in LUAD and LUSC [20,21]. 
3. Results 
3.1. Adenosquamous carcinoma have different growth patterns 
The main clinico-pathologic characteristics of the three patients with 
ASC are summarized in Table 1. The three tumors were at stages pT2- 
pT4. In all three patients, the LUAD area was larger than the LUSC 
area. All LUSC areas were homogeneously p40-positive, while all LUAD 
areas were p40-negative by immunohistochemistry (Fig. 1). Two LUAD 
were TTF-1 positive (P118 & P119), while the other one was negative for 
both TTF1 and Napsin A. There was a predominant acinar growth 
pattern of the LUAD component in all three ASCs (Fig. 1 and Supple-
mentary Fig. 2). Additional LUAD patterns were lepidic (P118 & P119) 
and solid (P119 & P120). Keratinization in the LUSC component was 
observed in P118 and P119. 
3.2. LUAD and LUSC within adenosquamous carcinoma are of 
monoclonal origin 
Overall, we found 759 non-synonymous mutations in 441 genes 
across the six tumor components of the three ASC. The proportion of 
shared mutations of LUSC and LUAD components of P118, P119 and 
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P120 were 54 %, 28 % and 78 %, respectively (Fig. 2a, Supplementary 
table 2). The six separately analyzed tumor areas harbored a median of 
72 (range 53–254) non-synonymous somatic mutations. Including syn-
onymous mutations, the median of mutational burden was 3.5 
mutations (mut)/Mb (range 2.3–11.6). It was highest in P120 (LUAD 
11.6 mut/Mb and LUSC 11.3 mut/Mb) and lower in P118 (LUAD 3.5 
mut/Mb, LUSC 2.3 mut/Mb) and P119 (LUAD 3.3 mut/Mb, LUSC 3.4 
mut/Mb). 
Across the samples, most of the mutations in driver genes were clonal 
(Fig. 2b). The analysis of P118 displayed four shared cancer gene mu-
tations, of which only EGFR exon 19 deletion was clonal in both. TP53 p. 
Gln192* was mutated in both components and a further TP53 p. 
Gly108Asp mutation was detected only in the LUAD component. P119 
shared three clonal mutations MET, BRAF and P119 ACVR1B mutations. 
We detected shared cancer gene mutations between the components of 
P120. Moreover, one clonal STRN mutation was detected in P120 LUAD. 
Further, four clonal and one subclonal private mutations were found in 
the LUSC component. 
Gene copy number data from all patients and tumor components 
revealed high concordance between the two components (Fig. 2c). 
3.3. Evolutionary history of genetic alterations 
Most mutations in known cancer driver genes were truncal (Fig. 3). 
Most mutated cancer genes were known as typical for LUAD such as 
EGFR, MET and BRAF. P118 harbored a deletion in EGFR exon 19, a 
well-known driver gene in LUAD [6,22]. We found only KMT2D in P120, 
but not any other mutations in LUSC typical driver genes (Fig. 4). 
Interestingly, there were fewer mutations in the branches than truncal 
Table 1 
Clinico-pathological features of the adenosquamous carcinomas at the time of 
resection.  
Patient P118 P119 P120 
Age (at resection) 62 80 66 
Sex male female female 
Smoking status former unknown former 
TNM classification pT4 pNo 
cM0 
pT2a pN0 
cM0 
pT3 pN1 cM0 
Maximum Tumor 
diameter 
8 cm 4.9 cm 8 cm 
Lymphatic or venous 
invasion 
no no yes (lymphatic & 
venous) 
Pleural invasion yes yes yes 
Spread through air spaces 
(STAS) 
no no no 
Predominant LUAD 
pattern (%) 
acinar (90 
%) 
acinar (80 
%) 
acinar (80 %) 
Fraction of LUAD 
component 
70 % 
(TTF1+) 
60 % 
(TTF1+) 
60 % (TTF1- & 
Napsin A -) 
Fraction of LUSC 
component 
30 % 
(p40+) 
40+
(p40pos) 
40+ (p40+)  
Fig. 1. Adenosquamous carcinoma of the lung. Representative micrographs of a hematoxylin-eosin stained ASC (case P118) (a), the LUAD component immuno-
stained with an antibody recognizing the lineage marker TTF-1 (b) and the LUSC immunostained with an antibody recognizing the specific marker p40 (c). 
Fig. 2. LUAD and LUSC within adenosquamous carcinoma are of monoclonal origin. (a) Venn diagrams display the number of non-synonymous mutations per 
patient that are common between the LUAD (blue) and LUSC (red) components. The size of the circles is proportional to the number of mutations. (b) Heatmap 
illustrates the cancer cell fraction of selected mutations. Clonal mutations are illustrated with a diagonal line. (c) Copy number aberrations of every sample are 
displayed. (For interpretation of the references to colour in the Figure, the reader is referred to the web version of this article). 
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mutations. 
Truncal copy number variations (CNVs) might also play a role as 
drivers of malignancy. Loss of regions at chr 3p, 15q, 19p and an 
amplified locus at chr 5p were identified across all samples. Losses in 
regions of chr 6, 17 and 20 in LUAD of P118 were normal in LUSC. LUAD 
P119 had private losses in regions of chr 19, whereas the LUSC 
component harbored private losses in chr 12. Further private losses in 
chr 12 were identified in P120 LUSC. Regions of chr 9 were gained in 
LUSC P120 but lost in the LUAD component. Notably, there was truncal 
loss of STK11 at 19p13 in P118 and P120. In P120, we detected a truncal 
amplified region on 3q including TP63 and SOX2 (Fig. 3). SOX2 
amplification was confirmed using FISH (Supplementary Fig. 1). 
Given that truncal genomic alterations are likely acquired prior to 
the branching of the two components, we sought to investigate whether 
mutational signatures are shared or change over time (Fig. 3). For all our 
three ASC, we found different patterns of signatures as well as 
commonalities. 
Trunks of all three tumors displayed signatures 1 and 4. The truncal 
mutations of P118 and P119 were also characterized by the APOBEC 
signature 13. In addition, trunks of P118 and P120 carried signature 5. 
The signatures changed drastically in the branches. Whereas, P119 
LUAD was found to exhibit signatures 1, 2, 4 and 13 the LUSC compo-
nent only exhibited signature 1 and 6. Signature 1 contributed to more 
than 50 % of the mutations of all LUAD/LUSC branches, except of P118 
LUAD where it was not present at all. The smoking signature was also 
seen in both components of P120 and in P119 LUAD, but not P119 LUSC. 
Several signatures were observed exclusively in a single branch, 
including signature 13 in P119 LUAD, signature 6 in P119 LUSC and 
Fig. 3. Mutational signatures and genomic alterations of truncal and branch mutations in LUAD and LUSC. Evolution of the somatic genetic alterations illustrates the 
changes in mutational processes. Pie charts delineate the proportion of mutational signatures. Black, blue, and red lines represent the trunk, the LUAD branch, and 
the LUSC branch, respectively. Mutations or indels in cancer genes are noted next to branches. STK11 loss and SOX2 amplification are noted in bold. (For inter-
pretation of the references to colour in the Figure, the reader is referred to the web version of this article). 
Fig. 4. Non-synonymous mutation plot and comparison with TCGA LUAD and LUSC datasets. The heatmap depicts a comparison between the non-synonymous genes 
in the dataset of Bailey et al. that represents the most significantly mutated genes in classic LUAD (middle) and LUSC (right) 13. The figure shows a comparison 
between the three ASC patients (left), TCGA LUAD (TCGA, Nature 2014) and LUSC (TCGA, Provisional) datasets from the cBioPortal (http://cbioportal.org) Left plot 
LUAD = adeno component of ASC; LUSC = squamous cell carcinoma component of ASC. Order of the patients within the components of LUAD is P118, P119, P120 
and in LUSC P118, P119, P120. 
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signature 17 in P120 LUAD. Notably, signature 6 was observed in P119 
LUSC, which is not common in classic LUSC, but prominent in LUAD. 
4. Discussion 
ASC had originally been assumed to be a mixed tumor with a poly-
clonal origin consisting of two separate tumors until recent gene panel 
sequencing demonstrated shared mutations in LUAD and LUSC [5,6]. 
Here we provided unequivocal evidence for a monoclonal origin of the 
LUAD and LUSC components in ASC based on comprehensive muta-
tional patterns and CNVs obtained by WES. 
In our study, truncal genetic alterations included not only mutations 
in common cancer genes such as TP53 but also the typical driver gene 
mutations of LUAD in EGFR, BRAF and deletions of STK11 (Fig. 3). This 
is in line with previous studies using NGS panels or selected single gene 
testing of the two ASC components [5,6]. In particular, activating EGFR 
mutations have been shown to be at least as common in ASC as in 
classical LUAD ranging from approximately 15 % in Western patients to 
50 % in Asian patients, while they have been reported in only ~2% of 
LUSC [22–24]. This has also been emphasized by a recent study of Lin 
et al., who showed that the genomic ASC profiles by targeted sequencing 
looked more similar to classic LUAD than LUSC [6]. In accordance, 
typical LUAD mutations were predominant in our study. We identified 
only one KMT2D mutation as a putative LUSC driver [25,26]. KMT2D 
mutations are not exclusive for LUSC as they occur, albeit less 
frequently, also in LUAD according to TCGA (21 % vs. 8%) (http://cbiop 
ortal.org) [27]. In summary, the clonal relationship between the two 
components in ASC together with the presence of more LUAD than LUSC 
mutations suggest that ASC originates from an early LUAD ancestor. 
Interestingly, 23 lymph node metastases from 12 patients in the recent 
study by Lin et al. contained either LUAD or ASC (11, each), while only 
one consisted of pure LUSC [6]. This further supports that an early 
LUAD-like ancestor might not only be the driving force during tumor 
development but also during progression. 
Tumor evolution is influenced by exogenous and endogenous 
mutational processes that shape the spectra of different mutational 
signatures [28]. It was previously demonstrated that LUAD and LUSC 
share common signatures of type 1 (CpG deamination and aging), 2 
(APOBEC), 4 (smoking), 5 (transcriptional strand bias for T > C) 13 
(APOBEC). In addition, LUAD was found to display signatures 6 
(defective DNA-repair) and 17 (unknown origin) [21]. In our study, the 
trunks of all three ASC were dominated by aging and smoking-related 
signatures 1 and 4, respectively, which is partly explained by a smok-
ing history of the patients. Interestingly, the distribution of signatures 
changed markedly in the LUAD and LUSC branches. This is in line with 
previous studies on LUAD, LUSC and breast cancer showing that muta-
tional signatures may change from the trunk to branches [19,29,30]. 
Change in mutation signatures can provide additional insights into the 
development and evolutionary traits of malignant tumors [31,32]. 
Recently, Richard and colleagues found an association between muta-
tional signatures and clinical efficacy of nivolumab, an immune check-
point inhibitor, in lung cancer patients [33]. In our study, the trunks of 
all three ASC were dominated by aging and smoking-related signatures 1 
and 4, respectively, which is partly explained by a smoking history of the 
patients. However, the distribution of signatures changed markedly in 
the LUAD and LUSC branches. Notably, we did not observe a systematic 
accumulation of the APOBEC signature, which was previously shown to 
drive mutagenesis and subclonal expansion in LUAD and LUSC [31]. 
Taken together, we found that most of the genomic alterations accu-
mulated in the trunk before branching and changed over time. Aging 
and smoking-induced signatures 1 and 4 were the most prominent and 
present in almost all lineages suggesting a promoting role in tumor 
development and progression. Further studies are needed to better un-
derstand the biological significance and potential clinical impact of 
mutational signatures in lung cancer, and their association with histo-
logical transdifferentiation. 
Our gene copy number data suggest persistent genomic instability as 
chromosomal aberrations are detected even after branching of the two 
components. The high overall concordance between the chromosomal 
copy number aberrations profiles of the components support our pre-
vious data from metastatic LUAD showing that most aberrant genomic 
events are truncal with only limited heterogeneity between primary 
tumors and matched metastases [34]. Nevertheless, the two ASC com-
ponents had private CNVs, which were similar to the CNVs known to be 
typical for their pure morphological counterparts, i.e. classical LUAD 
and LUSC, respectively [35]. For example, the trunk of P120 and P119 
LUSC had an amplified region on 3q including SOX2. SOX2 expression is 
known as a common feature of squamous differentiation, and SOX2 
amplification occurs in 40 % of LUSC but is almost never seen in LUAD 
[36]. Thus, it is possible that SOX2 amplification served as a genomic 
precondition to facilitate the AST of truncal LUAD to LUSC in P119 and 
P120. This hypothesis would be in line with previous evidence from a 
mouse model, in which overexpression of SOX2 induced squamous dif-
ferentiation [37,38]. In fact, AST was linked to silenced TTF-1 expres-
sion in the pre-clinical mouse model, suggesting that the differential 
regulation of TTF-1 and SOX2 expression might be involved in the 
transformation process. In P120, AST is difficult to prove. The truncal 
nature of SOX2 amplification and KMT2D mutation could point towards 
a reverse sequence with a LUSC-type ancestor clone despite the truncal 
STK11 loss. Deletion of STK11, which we found in P118 and P120, might 
pinpoint another mechanism of plasticity and AST. STK11 alterations in 
general, occur in up to 14 % in classic LUAD but in only 2% of classical 
LUSC (http://cbioportal.org) [39]. There is pre-clinical evidence from 
mouse models suggesting that different mechanisms in STK11 deficiency 
can lead to a transition from LUAD to LUSC [40,41]. Concluding, AST is 
a complex process that might be caused due to several different mech-
anisms that require further studies. 
The main limitation of this study is the low number of patients 
reflecting the rarity of the tumor. In fact, this is the first study to perform 
comprehensive WES on the two components of ASC separately. More-
over, the usage of archived FFPE blocks and contamination with non- 
tumor tissue negatively affect the resolution of our analysis. Neverthe-
less, our CNV data of SOX2 and STK11 support pre-clinical evidence of 
genomic driven mechanisms that could facilitate or mediate AST to 
LUSC. Although we discovered only KMT2D as a candidate mutation 
known to be typical but not exclusive for squamous differentiation, we 
cannot rule out a role of other mutations or mutational patterns. It is 
likely that AST in ASC is driven by both genetic and non-genetic 
mechanisms including transcriptional regulation and metabolic factors 
as discussed above. The role of epigenetic reprogramming has not yet 
been studied in the context of AST in ASC despite the paramount 
importance of epigenetics in shaping morphology [42]. 
5. Conclusion 
Our whole-exome analysis showed compelling evidence for a clonal 
relationship between the LUAD and LUSC components of ASCs, and the 
emergence from a common LUAD-like ancestor clone. Even if the results 
are ambiguous, identification of SOX2 amplification and STK11 loss in 
two of the three LUSC components, each, supports previous pre-clinical 
evidence for a role of these genes in AST. Further and more compre-
hensive studies with a larger sample size are needed to gain a better 
understanding of the mechanisms that drive transformation from LUAD 
to LUSC or LUSC to LUAD, including transcriptomics and epigenomics. 
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